The original success of Sildenafil undeniably revolutionized the medication landscape, but investing in companies strongly reliant on off-patent versions presents a uncertain picture. Despite early returns were impressive, the expiration of patents and the emergence of discounted alternatives have weakened the customer base. Consequently, a thoroug